Brief: Outlook Therapeutics Announces Commercial Launch Of Lytenava In Germany And UK For Treatment Of Wet AMD
02/06/2025 13:10
June 2 (Reuters) - Outlook Therapeutics Inc OTLK.O: OUTLOOK THERAPEUTICS® ANNOUNCES COMMERCIAL LAUNCH OF LYTENAVA™ (BEVACIZUMAB GAMMA) IN GERMANY AND THE UK FOR THE TREATMENT OF WET AMD OUTLOOK THERAPEUTICS INC - LYTENAVA APPROVED FOR WET AMD IN EU AND UK Source text: ID:nGNX54rbXl Further company coverage: OTLK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce